Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sato, S.
Right arrow Articles by Hattori, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, S.
Right arrow Articles by Hattori, N.
Related Collections
Right arrow Parkinson's disease/Parkinsonism
NEUROLOGY 2005;64:1081-1083
© 2005 American Academy of Neurology
Brief Communications

Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease

Shigeto Sato, MD, Yoshikuni Mizuno, MD and Nobutaka Hattori, MD, PhD

From the Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

8-Hydroxydeoxyguanosine (8-OHdG) has been used to evaluate oxidative stress. The authors investigated urinary 8-OHdG levels in 72 patients with Parkinson disease (PD) and in normal and disease control groups. The mean urinary 8-OHdG increased with the stage of PD and was not influenced by the current dose of DOPA. Our results suggest that urinary 8-OHdG is a potentially useful biomarker for evaluating the progression of PD.

Received June 2, 2004. Accepted in final form November 24, 2004.

Addresss correspondence and reprint requests to Dr. Nobutaka Hattori, Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113-8421, Japan; e-mail: nhattori{at}med.juntendo.ac.jp




This article has been cited by other articles:


Home page
 BrainHome page
M. Bogdanov, W. R. Matson, L. Wang, T. Matson, R. Saunders-Pullman, S. S. Bressman, and M. F. Beal
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Brain, February 1, 2008; 131(2): 389 - 396.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C.-W. Hu, C.-J. Wang, L. W. Chang, and M.-R. Chao
Clinical-Scale High-Throughput Analysis of Urinary 8-Oxo-7,8-Dihydro-2'-Deoxyguanosine by Isotope-Dilution Liquid Chromatography-Tandem Mass Spectrometry with On-Line Solid-Phase Extraction
Clin. Chem., July 1, 2006; 52(7): 1381 - 1388.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Jenner and C. W. Olanow
The pathogenesis of cell death in Parkinson's disease
Neurology, May 23, 2006; 66(10_suppl_4): S24 - S36.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.